![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00170963 |
This study will test the effectiveness and safety of a combination treatment in patients whose blood pressure is not controlled with a single medication
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: valsartan/amlodipine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Valsartan/Amlodipine 160/5 mg or 160/10 mg Versus Valsartan 160 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Valsartan 160 mg Monotherapy |
Estimated Enrollment: | 947 |
Study Start Date: | October 2004 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined exclusion criteria may apply.
Study ID Numbers: | CVAA489A2305 |
Study First Received: | September 10, 2005 |
Last Updated: | November 13, 2006 |
ClinicalTrials.gov Identifier: | NCT00170963 |
Health Authority: | United States: Food and Drug Administration |
Hypertension, high blood pressure, valsartan, amlodipine |
Calcium, Dietary Vascular Diseases Valsartan Amlodipine Hypertension |
Membrane Transport Modulators Vasodilator Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Calcium Channel Blockers |
Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |